Overview

Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This study will be performed in normal men whose endogenous testosterone production has been temporarily suppressed by the administration of a single dose of 120 mg of the oral GnRH antagonist Relugolix, which is approved for the treatment of prostate cancer, and can suppress endogenous testosterone biosynthesis for 48-72 hours after a single dose.

Phase:

PHASE1

Details

Lead Sponsor:

University of Washington

Collaborator:

Washington State University

Treatments:

Curcumin
relugolix
testosterone undecanoate